Get access to Protocol
The genetic testing company announced it will go public via a SPAC with Richard Branson's Virgin Group, at a valuation of $3.5 billion. Branson was an early investor in the company.
CEO Anne Wojcicki and Branson both invested $25 million into the $250 million PIPE accompanying the SPAC. The company is set to go public in the second quarter of this year.